Methods for treating copd by administering an il-33 antagonist

A method for treating chronic obstructive pulmonary disease (COPD) in a subject in need thereof comprising administering to the subject:

• an initial dose of about 300 mg of an antibody or antigen-binding fragment thereof that specifically binds interleukin-33 (IL-33) and comprises three heavy chain complementarity determining region (HCDR) sequences comprising SEQ ID NOs:
• 4, 6 and 8, and three light chain complementarity determining region (LCDR) sequences comprising SEQ ID NOs:
• 12, 14 and 16;
• and
• one or more subsequent doses of about 300 mg of the antibody or antigen-binding fragment thereof;
• or
• a method for treating moderate-to-severe chronic obstructive pulmonary disease (COPD) in a subject in need thereof comprising administering to the subject:
• an initial dose of about 300 mg of an antibody that specifically binds interleukin-33 (IL-33), wherein the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:
• 18, and a light chain comprising the amino acid sequence of SEQ ID NO:
• 20;
• and
• one or more subsequent doses of about 300 mg of the antibody,
• wherein the antibody is administered subcutaneously every other week;
• or
• a method for treating moderate-to-severe chronic obstructive pulmonary disease (COPD) in a subject in need thereof comprising administering to the subject:
• an initial dose of about 300 mg of an antibody that specifically binds interleukin-33 (IL-33), wherein the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:
• 18, and a light chain comprising the amino acid sequence of SEQ ID NO:
• 20;
• and
• one or more subsequent doses of about 300 mg of the antibody,
• wherein the antibody is administered subcutaneously every four weeks.

A method for reducing annualized rate of moderate-to-severe acute exacerbations of chronic obstructive pulmonary disease (AECOPD) in a subject having moderate-to-severe chronic obstructive pulmonary disease (COPD) comprising administering to the subject:

• an initial dose of about 300 mg of an antibody or antigen-binding fragment thereof that specifically binds interleukin-33 (IL-33) and comprises three heavy chain complementarity determining region (HCDR) sequences comprising SEQ ID NOs:
• 4, 6 and 8, and three light chain complementarity determining region (LCDR) sequences comprising SEQ ID NOs:
• 12, 14 and 16;
• and
• one or more subsequent doses of about 300 mg of the antibody or antigen-binding fragment thereof;
• or
• a method for reducing annualized rate of moderate-to-severe acute exacerbations of chronic obstructive pulmonary disease (AECOPD) in a subject having moderate-to-severe chronic obstructive pulmonary disease (COPD) comprising administering to the subject:
• an initial dose of about 300 mg of an antibody that specifically binds interleukin-33 (IL-33), wherein the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:
• 18, and a light chain comprising the amino acid sequence of SEQ ID NO:
• 20;
• and
• one or more subsequent doses of about 300 mg of the antibody,
• wherein the antibody is administered subcutaneously every other week;
• or
• a method for reducing annualized rate of moderate-to-severe acute exacerbations of chronic obstructive pulmonary disease (AECOPD) in a subject having moderate-to-severe chronic obstructive pulmonary disease (COPD) comprising administering to the subject:
• an initial dose of about 300 mg of an antibody that specifically binds interleukin-33 (IL-33), wherein the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:
• 18, and a light chain comprising the amino acid sequence of SEQ ID NO:
• 20;
• and
• one or more subsequent doses of about 300 mg of the antibody,
• wherein the antibody is administered subcutaneously every other week, wherein the subject is a former smoker;
• or
• a method for reducing annualized rate of moderate-to-severe acute exacerbations of chronic obstructive pulmonary disease (AECOPD) in a subject having moderate-to-severe chronic obstructive pulmonary disease (COPD) comprising administering to the subject:
• an initial dose of about 300 mg of an antibody that specifically binds interleukin-33 (IL-33), wherein the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:
• 18, and a light chain comprising the amino acid sequence of SEQ ID NO:
• 20;
• and
• one or more subsequent doses of about 300 mg of the antibody,
• wherein the antibody is administered subcutaneously every four weeks;
• or
• a method for reducing annualized rate of moderate-to-severe acute exacerbations of chronic obstructive pulmonary disease (AECOPD) in a subject having moderate-to-severe chronic obstructive pulmonary disease (COPD) comprising administering to the subject:
• an initial dose of about 300 mg of an antibody that specifically binds interleukin-33 (IL-33), wherein the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:
• 18, and a light chain comprising the amino acid sequence of SEQ ID NO:
• 20;
• and
• one or more subsequent doses of about 300 mg of the antibody,
• wherein the antibody is administered subcutaneously every four weeks, wherein the subject is a former smoker.